公开(公告)号：WO2013011368A9

公开(公告)日：2013-03-21

申请号：PCT/IB2012001400

申请日：2012-07-18

Applicant: TEVA PHARMA ,  AHARONI AMIR ,  ZARETZKY MARIANNA

Inventor： AHARONI AMIR ,  ZARETZKY MARIANNA

IPC: C12P21/06

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/1793 ,  A61K38/2006 ,  A61K45/06 ,  C07K14/54 ,  A61K2300/00

Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.

Abstract translation: 提供与hIL-17高亲和力的工程化可溶性hIL-17RA受体，其抑制细胞中下游IL17A诱导的信号传导事件。 还提供了抑制细胞中hIL-17A诱导的CXCL1和/或IL-6分泌的方法，以及治疗受试者的炎症和/或炎性病症的方法。

公开(公告)号：WO2013011368A2

公开(公告)日：2013-01-24

申请号：PCT/IB2012/001400

申请日：2012-07-18

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  AHARONI, Amir ,  ZARETZKY, Marianna

Inventor： ZARETZKY, Marianna

IPC: C07K14/54

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/1793 ,  A61K38/2006 ,  A61K45/06 ,  C07K14/54 ,  A61K2300/00

Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.

Abstract translation: 提供了对hIL-17具有高亲和力的工程可溶性hIL-17RA受体，其抑制下游IL17A诱导细胞中的信号传导事件。 还提供了抑制细胞中hIL-17A诱导的CXCL1和/或IL-6分泌的方法，以及治疗受试者的炎症和/或炎症性疾病的方法。